Turner syndrome is associated with increased cardiovascular morbidity and mortality

Czech version

Authors: M. Berková ¹; Z. Berka ²; Z. Krčová ³
Authors‘ workplace: I. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta prof. MUDr. Jan Lukl, CSc. ¹; II. interní klinika Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr. Vlastimil Procházka, Ph. D. ²; Ústav patologie Lékařské fakulty UP a FN Olomouc, přednosta doc. MUDr. Martin Tichý, CSc. ³
Published in: Vnitř Lék 2009; 55(5): 523-528
Category: Case Reports

Overview

The authors present a case of an acute myocardial infarction in a patient with Turner syndrome, leading to the death of the patient. An emphasis is put on the need of a thorough examination of cardiovascular system, specialized on congenital heart disease including aortic dilatation with the risk of dissection, and early development of ischemic heart disease. Regular monitoring as well as adequate therapy in patients suffering from this genetically determined disorder is recommended.

Key words:
Turner syndrome –⁠ ischemic heart disease –⁠ myocardial infarction –⁠ congenital heart disease

Sources

1. Elsheikh M, Dunger DB, Conway GS et al. Turner Syndrome in Adulthood. Endocrine Reviews 2002; 23 : 120–140.

2. Zapletalová J, Šnajderová M. Turnerův syndrome. Praha: Galén 2003 : 149–159.

3. Gravhold CH, Juul S, Naeraa RW et al. Morbidity in Turner syndrome. J Clin Epidemiol 1998; 51 : 147–158.

4. Ross JL, Feuillan P, Long LM et al. Lipid abnormalities in Turner syndrome. J Pediatr 1995; 126 : 242–245.

5. Garden AS, Diver MJ, Fraser WD. Undiagnosed morbidity in adult women with Turner’s syndrome. Clin Endocrinol (Oxf) 1996; 45 : 589–594.

6. Gravholt CH, Naeraa RW, Nyholm B et al. Glucose metabolism, lipid metabolism and cardiovascular risk factors in adult Turner’s syndrome. The impact of sex hormone replacement. Diabetes care 1998; 21 : 1062–1070.

7. Van Teunenbroek A, de Muinck Keizer Schrama SM, Aanstoot HJ et al. Carbohydrate and lipid metabolism during various growth hormone dosing regimens in girls with Turner syndrome. Dutch working group on Growth Hormone. Metabolism 1999; 48 : 7–14.

8. Sylven L, Hagenfeldt K, Brondum-Nielsen K et al. Middle-aged women with Turner’s syndrome. Medical status, hormonal treatment, and social life. Acta Endocrinol 1991; 125 : 359–365.

9. Lanes R, Gunczler P, Palacios A et al. Serum lipids, lipoprotein lp(a), and plasminogen activator inhibitor-1 in patients with Turner’s syndrome before and during growth hormone and estrogen therapy. Fertil steril 1997; 68 : 473–477.

10. Ostberg JE, Donald AE, Halcox JPJ et al. Vasculopathy in Turner Syndrome: Arterial Dilatation and Intimal thickening without endothelial dysfunction. Clin Endocrinol Metabol 2005; 90 : 5161–5166.

11. Chlumský J, Kölbel F, Burešová M et al. Disekující aneuryzma aorty u nemocné s Turnerovým syndromem. Vnitř Lék 2000; 46 : 34–36.

12. Van PL, Bakalov V, Bondy CA. Monosomy for the X chromosome is associated with an atherogenic lipid profile. J Clin Endocrinol Metab 2006; 91 : 2867–2870.

13. Van PL, Bakalov V, Zinn A et al. Maternal X-chromosome, visceral adiposity and lipid profile. JAMA 2006; 295 : 1373–1374.